FcRn Blocker Enters Autoimmune Myositis: Efgartigimod Phase 3 Trial Meets Endpoint

Autoimmune myositis progressively erodes muscle strength and can sometimes affect organs such as the skin and lungs, yet treatment has long relied on broadly suppressing the immune response. Now, a drug targeting pathogenic IgG antibodies has crossed a key threshold: argenx announced that subcutaneous efgartigimod met the primary efficacy endpoint in the Phase 3 ALKIVIA trial.

In this randomized, double-blind, placebo-controlled study, the VYVGART Hytrulo treatment group had a Total Improvement Score (TIS) at week 52 that was 15.4 points higher than that of the placebo group, a statistically significant difference. The Phase 3 analysis announced by the company included 175 patients with immune-mediated necrotizing myopathy or dermatomyositis; the entire seamless Phase 2/3 program enrolled 264 participants worldwide.

TIS is not a single muscle-strength test, but a 0-to-100-point scale integrating six measures of disease activity and physical function. Scores of 20, 40, and 60 points represent minimal, moderate, and major improvement, respectively. This composite assessment can capture the multidimensional changes associated with myositis, but the 15.4-point between-group difference still needs to be considered alongside the actual mean scores in both groups, the proportions reaching each improvement threshold, and changes in daily functioning to determine the magnitude of benefit patients may perceive.

Efgartigimod is an IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), blocking the recycling of IgG and thereby reducing circulating IgG, including autoantibodies that may contribute to damage in muscles and other tissues. It is already used in other autoimmune neurological diseases; the ALKIVIA results extend this mechanism into the fields of rheumatology, immunology, and myositis.

This Phase 3 success is not an isolated signal. The earlier Phase 2 portion of ALKIVIA, involving 89 participants, showed that after 24 weeks of treatment, the mean TIS was 50.45 points in the efgartigimod group and 35.65 points in the placebo group. At least moderate improvement was achieved by 79% and 47%, respectively, while major improvement was achieved by 34% and 9.5%. The median time to minimal improvement was also shorter in the treatment group, at 30 days, compared with 72 days in the placebo group. At that time, the proportions of patients experiencing treatment-emergent adverse events were similar between the two groups, supporting the study’s progression to Phase 3.

However, the findings released so far remain company-provided topline results. Complete data for each Phase 3 group, whether the benefits are consistent across different myositis subtypes, how long responses persist, and infection or other safety events have not yet been fully presented in a peer-reviewed paper or on the trial registry results page. Even if a subsequent application is approved, whether the drug can reduce the use of corticosteroids and other immunosuppressants will also be an important criterion in determining its clinical role.